Form 4: iRhythm Director Jason Patten Granted 2,218 RSUs

iRhythm Holdings, Inc. Director Jason Patten was granted 2,218 restricted stock units, vesting over three years.

Summary

• Jason H Patten, a Director of iRhythm Holdings, Inc. (IRTC), acquired 2,218 restricted stock units (RSUs) on March 12, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest in three equal annual installments of 33.33%, beginning on March 12, 2027, and continuing on each one-year anniversary thereafter.
• Vesting is contingent upon Jason H Patten's continued service as a director through each vesting date.
• Following this transaction, Jason H Patten beneficially owns a total of 4,436 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the RSU grant aligns the director's long-term interests with shareholder value, a common and effective compensation strategy.

Positives

• The grant of restricted stock units aligns the director's long-term financial interests with those of the shareholders, incentivizing sustained company performance.
• Equity compensation is a standard and effective method for attracting and retaining experienced board members.

Negatives

• The RSUs have no immediate cash value and are subject to a multi-year vesting schedule, meaning the director must remain with the company to realize the full value.
• The ultimate value of the grant is dependent on the future market price of iRhythm Holdings, Inc. common stock.

Risks

• The value of the granted RSUs is subject to the inherent volatility and performance of iRhythm Holdings, Inc.'s common stock.
• Forfeiture of unvested RSUs will occur if Jason H Patten ceases to be a service provider to the company before the scheduled vesting dates.

Future Outlook

The vesting schedule for the restricted stock units extends through March 2029, indicating a long-term commitment and alignment of the director's interests with the company's future performance and shareholder value creation.

Industry Context

StockSavvy.ai notes that granting restricted stock units to directors is a common practice across industries, particularly in the healthcare technology sector, to align leadership incentives with long-term company growth and shareholder returns. This type of equity compensation is a standard component of a competitive director compensation package.

Comparison to Industry Standards

• The structure of this RSU grant, with a multi-year vesting schedule, is consistent with typical executive and director compensation practices observed in publicly traded companies within the medical device and digital health sectors, such as Dexcom (DXCM) or Masimo (MASI).
• The grant size for a director is within a reasonable range for a company of iRhythm's market capitalization, comparable to similar grants at peer companies aimed at retaining experienced board members.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial incentives with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this specific filing, though it reflects standard executive compensation practices.

Next Steps

• The company will continue to monitor the vesting of these restricted stock units according to the established schedule.

Key Dates

Keywords

iRhythm Holdings, IRTC, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction